EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Ginwa Enterprise Group's Enterprise Value is ¥1,595.4 Mil.
Ginwa Enterprise Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-20.8 Mil. Therefore, Ginwa Enterprise Group's EV-to-FCF for today is -76.59.
The historical rank and industry rank for Ginwa Enterprise Group's EV-to-FCF or its related term are showing as below:
SHSE:600080'
s EV-to-FCF Range Over the Past 10 Years
Min: -990.28 Med: 20.66 Max: 1883.54
Current: -76.59
During the past 13 years, the highest EV-to-FCF of Ginwa Enterprise Group was 1883.54. The lowest was -990.28. And the median was 20.66.
SHSE:600080's EV-to-FCF is ranked worse than 100% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs SHSE:600080: -76.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ginwa Enterprise Group (SHSE:600080) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ginwa Enterprise Group's PE Ratio (TTM) for today is calculated as:
Ginwa Enterprise Group's share price for today is ¥4.94.
Ginwa Enterprise Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Ginwa Enterprise Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ginwa Enterprise Group EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ginwa Enterprise Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Ginwa Enterprise Group's EV-to-FCF falls into.
Ginwa Enterprise Group's current Enterprise Value is ¥1,595.4 Mil.
Ginwa Enterprise Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-20.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ginwa Enterprise Group (SHSE:600080) has a EV-to-FCF of -76.59 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ginwa Enterprise Group and its competitors. According to the industry distribution chart, Ginwa Enterprise Group ranks #999999 out of 563 companies in the Drug Manufacturers industry.
Is Ginwa Enterprise Group's EV-to-FCF too high?
Ginwa Enterprise Group's current EV-to-FCF is -76.59. Based on the distribution chart, Ginwa Enterprise Group ranks #999999 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Ginwa Enterprise Group has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ginwa Enterprise Group's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ginwa Enterprise Group ranks #999999 out of 563 companies for EV-to-FCF. This places Ginwa Enterprise Group in the lower half of its industry. The industry median EV-to-FCF is 20.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Ginwa Enterprise Group and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ginwa Enterprise Group's current EV-to-FCF is -76.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ginwa Enterprise Group stock overvalued right now?
Based on GuruFocus' analysis, Ginwa Enterprise Group (SHSE:600080) is currently considered Possible Value Trap. The stock's GF Value™ is ¥7.53, compared to a current price of ¥4.94 — trading 34.4% below its estimated fair value. The current EV-to-FCF is -76.59. Ginwa Enterprise Group's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Ginwa Enterprise Group (SHSE:600080), the current EV-to-FCF is -76.59 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ginwa Enterprise Group (SHSE:600080) Overvalued in 2026?
Based on GuruFocus' analysis, Ginwa Enterprise Group stock appears to be undervalued.
The current stock price of ¥4.94 is trading 34.4% below its estimated GF Value™ of ¥7.53.
GuruFocus considers Ginwa Enterprise Group to be Possible Value Trap.
Key valuation signals for SHSE:600080:
EV-to-FCF: -76.59
GF Value™: ¥7.53 vs. price of ¥4.94 (34.4% below fair value)
No single metric tells the full story. See the SHSE:600080 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ginwa Enterprise Group Inc operates in the pharmaceutical industry. The main business is the research and development, production, and sales of drugs, and the product line covers chemical drugs, Chinese patent medicines, raw materials, and health products. The dosage forms include tablets, capsules, granules, powders, mixtures, oral solutions, syrups, external solutions, and more than 100 varieties and specifications.
47GF Score
Get the complete analysis for SHSE:600080
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600080 has been successfully added to your 
